Kapadi Joins Diligent Pharma's Qualified Vendor Network, Streamlining Sponsor Access to Oncology Expertise

Raleigh, NC – February 2026 | Kapadi, Inc., a leading clinical research organization specializing in oncology and cell and gene therapy, has reached a significant industry milestone after being officially qualified by Diligent Pharma, a globally recognized provider of centralized vendor qualification and risk management solutions for clinical trials. This new qualification promises to streamline clinical trial startup for emerging and smaller biopharma companies that may lack in-house qualification resources—marking a notable advancement for accessible, high-quality research support.

Quality oversight remains at the heart of this development. Shane Baldwin, Director of Quality Assurance at Kapadi, emphasized the advantages for sponsors: "For our sponsors, this achievement confirms Kapadi's commitment to meeting the stringent, evolving standards required for modern clinical trials. With Diligent's respected third-party assessment, our partners can rely on Kapadi for audit-ready processes, full regulatory alignment, and global best practices—regardless of company size or trial complexity." Sponsors interested in reviewing Kapadi's qualification data are encouraged to request the documentation at the Diligent Pharma Qualification Portal.

Quality oversight remains at the heart of this development. Shane Baldwin, Director of Quality Assurance at Kapadi, emphasized the advantages for sponsors: "For our sponsors, this achievement confirms Kapadi's commitment to meeting the stringent, evolving standards required for modern clinical trials. With Diligent's respected third-party assessment, our partners can rely on Kapadi for audit-ready processes, full regulatory alignment, and global best practices—regardless of company size or trial complexity."

Sponsors interested in reviewing Kapadi's qualification data are encouraged to request the documentation at the Diligent Pharma Qualification Portal.
With this independent qualification, Kapadi, Inc. further cements its reputation for delivering tailored, best-in-class solutions in oncology, and cell- and gene therapy trials worldwide—ensuring sponsors of all sizes receive a flawless, trusted start to their research journeys.

About Kapadi

Kapadi, Inc. is a global CRO specializing in oncology and cell & gene therapy clinical trials. With headquarters in Raleigh, North Carolina, and offices across North America, Europe, Asia, and Australia, Kapadi delivers expertly navigated support for early-stage drug development and complex clinical programs. The company leverages advanced technology solutions and data-driven operations to streamline every facet of a clinical trial, accelerating breakthroughs in cancer treatment and other challenging diseases.

Kapadi's renowned team offers comprehensive, custom-curated solutions guiding biopharma clients from concept to commercialization in oncology and rare disease studies. Its extensive network of specialty sites and oncology experts, paired with robust regulatory knowledge, positions Kapadi to drive success for biotech and pharmaceutical sponsors across the globe. With a proven track record in planning, implementing, and evaluating immuno-oncology and gene therapy studies for both common and rare indications, Kapadi stands out for innovation, patient engagement, and unwavering commitment to scientific excellence.

About Diligent Pharma

 Diligent Pharma is a Quality and Compliance company specializing in vendor qualification and management for clinical trials. Headquartered in Princeton, New Jersey, Diligent Pharma connects pharmaceutical and biotech sponsors to a global network of qualified clinical trial service providers through its innovative Diligent360 platform. The company combines deep regulatory expertise with advanced technology solutions to transform the vendor qualification process, enabling sponsors to launch trials faster while maintaining the highest standards of compliance and quality.

Sponsors can access the Diligent360 platform to discover pre-qualified service providers, leverage existing audit reports, and make confident, risk-informed vendor decisions that accelerate trial startups while reducing qualification costs. Clinical trial service providers can join Diligent's qualified vendor network to gain visibility to sponsors worldwide, streamline RFI management through our DiligentRespond tool, and undergo a single rigorous qualification assessment rather than hosting redundant, individual sponsor audits. With an unwavering dedication to helping life-saving treatments reach patients faster, Diligent Pharma is transforming vendor management across the clinical trial industry.